🟢 Immix Biopharma is trading 5.57% up today after Mizuho lifted target to $26

Immix Biopharma is trading 5.57% higher at $12.58 after Mizuho maintained an Outperform rating and raised its price target to $26 from $15.

• The analyst cited NXC-201’s potential second indication and anticipated NEXICART-2 clinical data later in September.
• Biotechnology is up 2.55%, and major U.S. indexes are broadly higher, adding support, though the analyst action appears to be the stronger catalyst.